Lusefi (luseogliflozin) / Taisho  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lusefi (luseogliflozin) / Taisho
NCT02528019: Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Unknown status
4
100
Japan
DPP-4 inhibiotors, SGLT2 inhibitors, Glimepiride
Kurume University
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
08/17
08/18

Download Options